Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies
This review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases. Cefiderocol, a novel siderophore cephalosporin, has demonstrated effectiveness against carbapenem-resistant bacteria such as <i>Pseudomonas aerug...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/13/2/295 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850229860609294336 |
|---|---|
| author | Majid Eslami Amirabbas Safaripour Seyedeh Zahra Banihashemian Sahar Nikjoo Niaragh Mohammad Amin Hemmati Arefeh Shojaeian Setayesh Fakhariyan Atiye Rabbani Valentyn Oksenych |
| author_facet | Majid Eslami Amirabbas Safaripour Seyedeh Zahra Banihashemian Sahar Nikjoo Niaragh Mohammad Amin Hemmati Arefeh Shojaeian Setayesh Fakhariyan Atiye Rabbani Valentyn Oksenych |
| author_sort | Majid Eslami |
| collection | DOAJ |
| description | This review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases. Cefiderocol, a novel siderophore cephalosporin, has demonstrated effectiveness against carbapenem-resistant bacteria such as <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>. Clinical trials, including APEKS-NP and CREDIBLE-CR, affirm its efficacy for hospital-acquired pneumonia (HAP) but highlight concerns over increased mortality due to severe renal complications. Cefiderocol has shown superior outcomes in complicated urinary tract infections (cUTI) compared to imipenem–cilastatin. A comparison of colistin monotherapy versus combination therapy with meropenem for carbapenem-resistant infections revealed no significant improvement in clinical outcomes with combination therapy but noted delays in resistance development. Colistin–rifampicin combination therapy showed potential benefits for colistin-resistant <i>Acinetobacter baumannii</i>, although results were not statistically significant. SPR206, a polymyxin derivative, and durlobactam, a β-lactamase inhibitor, show promise in addressing these resistant strains, with durlobactam demonstrating efficacy in combination with sulbactam and imipenem–cilastatin. Additional studies investigated antibiotic strategies for resistant infections, including cefoperazone–sulbactam versus combination therapy with tigecycline, and examined infection-prevention strategies in surgical settings, comparing chlorhexidine–alcohol and povidone–iodine. This research highlights the importance of optimizing treatment regimens and infection-control measures across various healthcare settings, including neonatology and surgical care. |
| format | Article |
| id | doaj-art-13bb278e2ac1451b89d1b8deea7dcd89 |
| institution | OA Journals |
| issn | 2076-2607 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj-art-13bb278e2ac1451b89d1b8deea7dcd892025-08-20T02:04:02ZengMDPI AGMicroorganisms2076-26072025-01-0113229510.3390/microorganisms13020295Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative StudiesMajid Eslami0Amirabbas Safaripour1Seyedeh Zahra Banihashemian2Sahar Nikjoo Niaragh3Mohammad Amin Hemmati4Arefeh Shojaeian5Setayesh Fakhariyan6Atiye Rabbani7Valentyn Oksenych8Cancer Research Center, Semnan University of Medical Sciences, Semnan 35147-99442, IranDepartment of General Surgery, Yasuj University of Medical Sciences, Yasuj 75917-41417, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 35147-99442, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 35147-99442, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 35147-99442, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 35147-99442, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 35147-99442, IranStudent Research Committee, Semnan University of Medical Sciences, Semnan 35147-99442, IranFaculty of Medicine, University of Bergen, 5020 Bergen, NorwayThis review provides an overview of recent research and advancements in infection prevention and the treatment of drug-resistant bacterial diseases. Cefiderocol, a novel siderophore cephalosporin, has demonstrated effectiveness against carbapenem-resistant bacteria such as <i>Pseudomonas aeruginosa</i> and <i>Acinetobacter baumannii</i>. Clinical trials, including APEKS-NP and CREDIBLE-CR, affirm its efficacy for hospital-acquired pneumonia (HAP) but highlight concerns over increased mortality due to severe renal complications. Cefiderocol has shown superior outcomes in complicated urinary tract infections (cUTI) compared to imipenem–cilastatin. A comparison of colistin monotherapy versus combination therapy with meropenem for carbapenem-resistant infections revealed no significant improvement in clinical outcomes with combination therapy but noted delays in resistance development. Colistin–rifampicin combination therapy showed potential benefits for colistin-resistant <i>Acinetobacter baumannii</i>, although results were not statistically significant. SPR206, a polymyxin derivative, and durlobactam, a β-lactamase inhibitor, show promise in addressing these resistant strains, with durlobactam demonstrating efficacy in combination with sulbactam and imipenem–cilastatin. Additional studies investigated antibiotic strategies for resistant infections, including cefoperazone–sulbactam versus combination therapy with tigecycline, and examined infection-prevention strategies in surgical settings, comparing chlorhexidine–alcohol and povidone–iodine. This research highlights the importance of optimizing treatment regimens and infection-control measures across various healthcare settings, including neonatology and surgical care.https://www.mdpi.com/2076-2607/13/2/295carbapenempharmacokinetics<i>Acinetobacter baumannii</i><i>Pseudomonas aeruginosa</i>multidrug-resistant |
| spellingShingle | Majid Eslami Amirabbas Safaripour Seyedeh Zahra Banihashemian Sahar Nikjoo Niaragh Mohammad Amin Hemmati Arefeh Shojaeian Setayesh Fakhariyan Atiye Rabbani Valentyn Oksenych Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies Microorganisms carbapenem pharmacokinetics <i>Acinetobacter baumannii</i> <i>Pseudomonas aeruginosa</i> multidrug-resistant |
| title | Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies |
| title_full | Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies |
| title_fullStr | Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies |
| title_full_unstemmed | Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies |
| title_short | Innovative Antibiotic Therapies for Carbapenem-Resistant Gram-Negative Bacterial Infections: Clinical Efficacy, Safety, and Comparative Studies |
| title_sort | innovative antibiotic therapies for carbapenem resistant gram negative bacterial infections clinical efficacy safety and comparative studies |
| topic | carbapenem pharmacokinetics <i>Acinetobacter baumannii</i> <i>Pseudomonas aeruginosa</i> multidrug-resistant |
| url | https://www.mdpi.com/2076-2607/13/2/295 |
| work_keys_str_mv | AT majideslami innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT amirabbassafaripour innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT seyedehzahrabanihashemian innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT saharnikjooniaragh innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT mohammadaminhemmati innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT arefehshojaeian innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT setayeshfakhariyan innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT atiyerabbani innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies AT valentynoksenych innovativeantibiotictherapiesforcarbapenemresistantgramnegativebacterialinfectionsclinicalefficacysafetyandcomparativestudies |